Showing results (171-180 of 227) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Blood|April 20, 2002
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphomaAjay K Gopal, Joseph G Rajendran, Stephen H Petersdorf, et al.
Blood Advances|October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantationRyan D Cassaday, Barry E Storer, Mohamed L Sorror, et al.
British Journal of Haematology|January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphomaLihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Blood|May 30, 2008
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBrian G Till, Michael C Jensen, Jinjuan Wang, et al.
Blood|May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Blood|October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionJohn M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
Hematological Oncology|September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative statusMaika Onishi, Solomon A Graf, Leona Holmberg, et al.
Pageof 23